Life expectancy with high-risk multiple myeloma can vary significantly based on several factors. People whose myeloma relapses within one year of starting initial treatment generally have a shorter outlook compared to those with later relapses. Certain genetic changes in myeloma cells, known as high-risk cytogenetic Show Full Answer
Life expectancy with high-risk multiple myeloma can vary significantly based on several factors. People whose myeloma relapses within one year of starting initial treatment generally have a shorter outlook compared to those with later relapses. Certain genetic changes in myeloma cells, known as high-risk cytogenetic features, can make the cancer more resistant to treatment and lead to shorter survival times. However, recent treatment advances have greatly improved survival rates. About 60% of people with multiple myeloma now live at least 5 years after diagnosis. Some individuals experience long-term remission lasting decades, with approximately 14% of people living 20 years or more. A 2024 study suggests newer treatments are leading to deeper, longer-lasting remissions and even the possibility of a "practical cure" for some patients.
The stage of myeloma at diagnosis also impacts survival rates. Stage 1 patients have about an 82% five-year survival rate, while stage 2 is around 62%, and stage 3 is approximately 40%. Your individual outlook will depend on your specific genetic factors, age, overall health, and response to treatment.
May 11, 2025
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
